[go: up one dir, main page]

WO2007065010A3 - Anti-angiogenesis compounds - Google Patents

Anti-angiogenesis compounds Download PDF

Info

Publication number
WO2007065010A3
WO2007065010A3 PCT/US2006/046267 US2006046267W WO2007065010A3 WO 2007065010 A3 WO2007065010 A3 WO 2007065010A3 US 2006046267 W US2006046267 W US 2006046267W WO 2007065010 A3 WO2007065010 A3 WO 2007065010A3
Authority
WO
WIPO (PCT)
Prior art keywords
hif
angiogenesis compounds
inhibiting
angiogenesis
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/046267
Other languages
French (fr)
Other versions
WO2007065010A2 (en
Inventor
Jong Wan Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BizBiotech Co Ltd
HIF Bio Inc
Original Assignee
BizBiotech Co Ltd
HIF Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BizBiotech Co Ltd, HIF Bio Inc filed Critical BizBiotech Co Ltd
Publication of WO2007065010A2 publication Critical patent/WO2007065010A2/en
Publication of WO2007065010A3 publication Critical patent/WO2007065010A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods and pharmaceutical compositions for inhibiting expressions of HIF and HIF regulated genes, inhibiting angiogenesis, inducing cell cycle arrest in tumor cells, and treating cell proliferating diseases or conditions.
PCT/US2006/046267 2005-12-02 2006-12-04 Anti-angiogenesis compounds Ceased WO2007065010A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74174205P 2005-12-02 2005-12-02
US60/741,742 2005-12-02

Publications (2)

Publication Number Publication Date
WO2007065010A2 WO2007065010A2 (en) 2007-06-07
WO2007065010A3 true WO2007065010A3 (en) 2007-11-29

Family

ID=38092893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046267 Ceased WO2007065010A2 (en) 2005-12-02 2006-12-04 Anti-angiogenesis compounds

Country Status (1)

Country Link
WO (1) WO2007065010A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007048636B4 (en) 2007-10-02 2012-05-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Marker for the diagnosis of cancer
DE102009041241A1 (en) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 New heteroaromatic compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis, diabetic retinopathy, rheumatoid arthritis and polycythemia
DE102008057344A1 (en) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituted aryl compounds and their use
KR20110082570A (en) * 2008-11-14 2011-07-19 바이엘 쉐링 파마 악티엔게젤샤프트 Heteroaromatic Compounds for Use as HIF Inhibitors
AU2009316019A1 (en) * 2008-11-14 2010-05-20 Bayer Intellectual Property Gmbh Heterocyclically substituted aryl compounds as HIF inhibitors
DE102009041242A1 (en) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft New heterocyclically substituted aryl compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, ischemic cardiovascular diseases, heart attack, arrhythmia, stroke, and psoriasis
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2011141325A1 (en) 2010-05-08 2011-11-17 Bayer Pharma Aktiengesellschaft Hydroxyalkyl benzyl pyrazoles, and use thereof for the treatment of hyperproliferative and angiogenic diseases
MA34939B1 (en) 2010-05-08 2014-03-01 Bayer Ip Gmbh SUBSTITUTED HETEROCYCLYLBENZYL-PYRAZOLES AND THEIR USE
UY33452A (en) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag REPLACED TRIAZOLOPIRIDINS
UY34200A (en) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3- (FLUOROVINIL) PIRAZOLES AND ITS USE
UA111754C2 (en) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт SUBSTITUTED BENZILINDASOLS FOR THE APPLICATION OF BUB1-KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
HK1203946A1 (en) 2011-10-17 2015-11-06 Bayer Intellectual Property Gmbh Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors
UA112096C2 (en) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх SUBSTITUTED TRIASOLOPYRIDINES AND THEIR APPLICATIONS AS TTK INHIBITORS
JP6166289B2 (en) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted imidazopyridazine
JP2016514719A (en) * 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト Heteroaryl substituted indazole
HUE033131T2 (en) 2013-06-11 2017-11-28 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
EA032401B1 (en) 2014-09-19 2019-05-31 Байер Фарма Акциенгезельшафт BENZYL SUBSTITUTED INDAZOLES AS Bub1 INHIBITORS
EP3609883B1 (en) 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
KR102577731B1 (en) 2017-06-30 2023-09-14 솔루스첨단소재 주식회사 Organic compounds and organic electro luminescence device comprising the same
CN112110908A (en) * 2020-09-25 2020-12-22 山东大学 A kind of 1,3-disubstituted indazole compound and its preparation method and application
KR102588242B1 (en) * 2021-04-26 2023-10-12 주식회사 스탠다임 Indazole compounds with LRRK2 inhibitory activity
CN115636789A (en) * 2022-11-10 2023-01-24 上海泰坦科技股份有限公司 Preparation method of 3-iodoindazole
CN118772140A (en) * 2023-04-07 2024-10-15 四川大学 A class of compounds and their use in treating hDHODH-mediated diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387940B1 (en) * 1996-10-14 2002-05-14 Bayer Aktiengesellschaft Heterocyclylmethyl-substituted pyrazole derivatives
US20050187276A1 (en) * 2003-06-30 2005-08-25 Park Jong-Wan Compounds, compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387940B1 (en) * 1996-10-14 2002-05-14 Bayer Aktiengesellschaft Heterocyclylmethyl-substituted pyrazole derivatives
US20050187276A1 (en) * 2003-06-30 2005-08-25 Park Jong-Wan Compounds, compositions and methods

Also Published As

Publication number Publication date
WO2007065010A2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
WO2005030121A3 (en) Compounds, compositions and methods
WO2007065010A3 (en) Anti-angiogenesis compounds
WO2007123892A3 (en) Raf inhibitors and their uses
MX2009013729A (en) Imidazopyrazines as protein kinase inhibitors.
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
WO2009011850A3 (en) Novel therapeutic compounds
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
MY168762A (en) Certain chemical entities, compositions and methods
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009039337A3 (en) Inhibition of angiogenesis
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2010088368A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2007076161A3 (en) Compounds with therapeutic activity
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2006001956A3 (en) Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO2008091873A3 (en) Compositions and methods for the identification, assessment, prevention and therapy of thymic lymphoma or hamartomatous tumours
WO2011040613A8 (en) Therapeutic agent for tumor
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 19.09.2008.

122 Ep: pct application non-entry in european phase

Ref document number: 06844793

Country of ref document: EP

Kind code of ref document: A2